Cargando…

LTX-315-enabled, radiotherapy-boosted immunotherapeutic control of breast cancer by NK cells

LTX-315 is a nonameric oncolytic peptide in early clinical development for the treatment of solid malignancies. Preclinical and clinical evidence indicates that the anticancer properties of LTX-315 originate not only from its ability to selectively kill cancer cells, but also from its capacity to pr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yamazaki, Takahiro, Wennerberg, Erik, Hensler, Michal, Buqué, Aitziber, Kraynak, Jeffrey, Fucikova, Jitka, Zhou, Xi Kathy, Sveinbjørnsson, Baldur, Rekdal, Øystein, Demaria, Sandra, Galluzzi, Lorenzo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8366543/ https://www.ncbi.nlm.nih.gov/pubmed/34408925 http://dx.doi.org/10.1080/2162402X.2021.1962592

Ejemplares similares

LTX-315 (Oncopore™): A short synthetic anticancer peptide and novel immunotherapeutic agent
por: Camilio, Ketil André, et al.
Publicado: (2014)

The oncolytic peptide LTX-315 induces cell death and DAMP release by mitochondria distortion in human melanoma cells
por: Eike, Liv-Marie, et al.
Publicado: (2015)

Anticancer effect obtained against MCA205 sarcoma following treatment with the oncolytic peptide LTX-315 in combination with immune checkpoint inhibitors
por: Rekdal, Öystein, et al.
Publicado: (2015)

Complete regression and systemic protective immune responses obtained in B16 melanomas after treatment with LTX-315
por: Camilio, Ketil André, et al.
Publicado: (2014)

LTX-315 sequentially promotes lymphocyte-independent and lymphocyte-dependent antitumor effects
por: Liao, Hsin-Wei, et al.
Publicado: (2019)

Combining the oncolytic peptide LTX-315 with doxorubicin demonstrates therapeutic potential in a triple-negative breast cancer model
por: Camilio, Ketil A., et al.
Publicado: (2019)

Oncolytic peptide LTX-315 induces an immune-mediated abscopal effect in a rat sarcoma model
por: Nestvold, Janne, et al.
Publicado: (2017)

Intratumoral treatment of one tumor lesion with LTX-315 induces complete tumor regression and long-term specific protective immune responses in a metastatic rodent tumor model
por: Rekdal, Öystein, et al.
Publicado: (2014)

LTX-315 – a promising novel antitumor peptide and immunotherapeutic agent
por: Zweytick, Dagmar
Publicado: (2019)

The oncolytic peptide LTX-315 triggers immunogenic cell death
por: Zhou, H, et al.
Publicado: (2016)

The Novel Oncolytic Compound LTX-401 Induces Antitumor Immune Responses in Experimental Hepatocellular Carcinoma
por: Mauseth, Brynjar, et al.
Publicado: (2019)

The Cytolytic Amphipathic β(2,2)-Amino Acid LTX-401 Induces DAMP Release in Melanoma Cells and Causes Complete Regression of B16 Melanoma
por: Eike, Liv-Marie, et al.
Publicado: (2016)

The oncolytic peptide LTX-315 kills cancer cells through Bax/Bak-regulated mitochondrial membrane permeabilization
por: Zhou, Heng, et al.
Publicado: (2015)

Understanding the Biophysical Interaction of LTX-315 with Tumoral Model Membranes
por: Klaiss-Luna, Maria C., et al.
Publicado: (2022)

Converging focal radiation and immunotherapy in a preclinical model of triple negative breast cancer: contribution of VISTA blockade
por: Pilones, Karsten A., et al.
Publicado: (2020)

Enhanced T-lymphocyte infiltration in a desmoid tumor of the thoracic wall in a young woman treated with intratumoral injections of the oncolytic peptide LTX-315: a case report
por: Jebsen, Nina Louise, et al.
Publicado: (2019)

Immunoprophylactic and immunotherapeutic control of hormone receptor-positive breast cancer
por: Buqué, Aitziber, et al.
Publicado: (2020)

NK cells beat T cells at early breast cancer control
por: Buque, Aitziber, et al.
Publicado: (2020)

Publisher Correction: Immunoprophylactic and immunotherapeutic control of hormone receptor-positive breast cancer
por: Buqué, Aitziber, et al.
Publicado: (2020)

Calreticulin arms NK cells against leukemia
por: Fucikova, Jitka, et al.
Publicado: (2019)

Interventional Oncolytic Immunotherapy with LTX-315 for Residual Tumor after Incomplete Radiofrequency Ablation of Liver Cancer
por: Zhou, Guanhui, et al.
Publicado: (2022)

Cell cycle progression data on human skin cancer cells with anticancer synthetic peptide LTX-315 treatment
por: Santa-González, Gloria A., et al.
Publicado: (2020)

Biophysical Characterization of LTX-315 Anticancer Peptide Interactions with Model Membrane Platforms: Effect of Membrane Surface Charge
por: Koo, Dong Jun, et al.
Publicado: (2022)

PT-112 induces immunogenic cell death and synergizes with immune checkpoint blockers in mouse tumor models
por: Yamazaki, Takahiro, et al.
Publicado: (2020)

Oncolytic peptide LTX-315 induces anti-pancreatic cancer immunity by targeting the ATP11B-PD-L1 axis
por: Tang, Tianyu, et al.
Publicado: (2022)

TIM-3 levels correlate with enhanced NK cell cytotoxicity and improved clinical outcome in AML patients
por: Rakova, Jana, et al.
Publicado: (2021)

Immunofluorescence microscopy-based assessment of cytosolic DNA accumulation in mammalian cells
por: Sato, Ai, et al.
Publicado: (2021)

Immunotherapeutic Applications of NK Cells
por: Davis, Carter T., et al.
Publicado: (2015)

Cellular senescence in the response of HR(+) breast cancer to radiotherapy and CDK4/6 inhibitors
por: Klapp, Vanessa, et al.
Publicado: (2023)

Oncolytic peptides DTT-205 and DTT-304 induce complete regression and protective immune response in experimental murine colorectal cancer
por: Fleten, Karianne Giller, et al.
Publicado: (2021)

New immunotherapeutic paradigms for castration-resistant prostate cancer
por: Galluzzi, Lorenzo
Publicado: (2013)

Tetrahydrofurandiols (THF-diols), Leukotoxindiols (LTX-diols), and Endocrine Disruption in Rats
por: Markaverich, Barry M., et al.
Publicado: (2007)

Gangliosides Block Aggregatibacter Actinomycetemcomitans Leukotoxin (LtxA)-Mediated Hemolysis
por: Forman, Michael S., et al.
Publicado: (2010)

Evolution of Indications for Liver Transplantation (LTx) in the Years 2001–2017 in Poland
por: Koczkodaj, Paweł, et al.
Publicado: (2019)

CCL17/TARC and CCR4 expression in Merkel cell carcinoma
por: Rasheed, Kashif, et al.
Publicado: (2018)

Biological role of NK cells and immunotherapeutic approaches in breast cancer
por: Roberti, María P., et al.
Publicado: (2012)

Aggregatibacter actinomycetemcomitans LtxA Hijacks Endocytic Trafficking Pathways in Human Lymphocytes
por: Lally, Edward T, et al.
Publicado: (2020)

Aggregatibacter actinomycetemcomitans Leukotoxin (LtxA; Leukothera(®)): Mechanisms of Action and Therapeutic Applications
por: Vega, Brian A., et al.
Publicado: (2019)

Immunological configuration of ovarian carcinoma: features and impact on disease outcome
por: Fucikova, Jitka, et al.
Publicado: (2021)

Membrane localization of the Repeats-in-Toxin (RTX) Leukotoxin (LtxA) produced by Aggregatibacter actinomycetemcomitans
por: Brown, Angela C., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_keel6n9estg7kvb1p95rvnq8pe